Uremic Pruritus Clinical Trial
Official title:
Treatment of Uremic Pruritus With Inhaled PA101B in Patients With End-Stage Renal Disease Requiring Hemodialysis
Verified date | April 2018 |
Source | Patara Pharma |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a randomized, double blind, placebo-controlled, parallel-arm, multi-center, Phase 2,
proof-of-concept efficacy and safety study in patients with end-stage renal disease requiring
hemodialysis.
The purpose of the study is to determine the efficacy and safety profile of PA101B delivered
via eFlow high efficiency nebulizer in patients with uremic pruritus who are symptomatic
despite using standard treatments.
Status | Completed |
Enrollment | 70 |
Est. completion date | December 2016 |
Est. primary completion date | August 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: - Diagnosis of end-stage renal disease (ESRD) requiring hemodialysis for at least 3 months prior to the Screening Period - Receiving conventional hemodialysis (i.e., not hemofiltration or hemodiafiltration) - Pruritus present for at least 6 weeks of Screening - Mean pruritus severity score on a numerical rating scale (NRS) > 4 - Patient-Assessed Disease Severity Scale Type B or C at Screening - Documentation of a urea reduction ratio (URR) >65% or single-pooled Kt/V> 1.4 during Screening - Willing and able to provide written informed consent Exclusion Criteria: - Current or recent history of clinically significant medical condition, laboratory abnormality, or illness that could put the patient at risk or compromise the quality of the study data as determined by the investigator - Myocardial infarction within 6 months or unstable angina, acute coronary syndrome, or interventional coronary procedure within 2 months of Screening - Upper or lower respiratory tract infection (including sinus infection) within 4 weeks of Screening - Severely symptomatic cardiopulmonary disease defined by the use of home oxygen treatment, dyspnea at rest or with minimal exertion, uncontrolled arrhythmias (e.g. atrial fibrillation with inadequate rate control), or history of life-threatening arrhythmias (e.g. cardiac arrest or syncope related to arrhythmia) - Acute exacerbation of asthma or chronic obstructive pulmonary disease resulting in hospitalization or visit to an emergency department or urgent care clinic within 6 months of Screening - Hospitalization for any medical reason other than for a pre-planned procedure or dialysis access related procedure within the 2 weeks of Screening - Malignancy requiring active treatment with a systemic drug - Participation in any other investigation drug study within 4 weeks of Screening - Current or anticipated use of baclofen, gabapentin, pregabalin and nalbuphine for the treatment of pruritus - Current or anticipated use of glucocorticoids administered intravenously, orally, or transdermally - Pregnant or breastfeeding females, or if of child-bearing potential unwilling to practice acceptable means of birth control or abstinence during the study |
Country | Name | City | State |
---|---|---|---|
United States | Renal Medicine Associates | Albuquerque | New Mexico |
United States | Southeast Renal Research Institute | Chattanooga | Tennessee |
United States | Fresenius Medical Care of Evergreen Park | Evergreen Park | Illinois |
United States | US Renal Care | Gallup | New Mexico |
United States | Boise Kidney and Hypertension Institute | Meridian | Idaho |
United States | Valley Renal Medical Group | Northridge | California |
United States | Pines Clinical Research, Inc. | Pembroke Pines | Florida |
United States | Arizona Kidney Disease and Hypertension Center | Phoenix | Arizona |
United States | US Renal Care | Pine Bluff | Arkansas |
United States | Ridgewood Dialysis Center | Ridgewood | New York |
United States | North America Research Institute | San Dimas | California |
United States | Genesis Clinical Research | Tampa | Florida |
United States | Brookview Hills Research Associates LLC | Winston-Salem | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Patara Pharma |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Itching intensity | Numerical rating scale (NRS) | 7 weeks | |
Secondary | Pruritus-specific quality of life (QoL) | Skindex-10 | 7 weeks | |
Secondary | Pruritus-specific sleep quality | Itch MOS | 7 weeks | |
Secondary | Assessment of depression | Beck Depression Inventory-II | 7 weeks | |
Secondary | Patient Global Impression of Change (PGIC) | 7 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04728984 -
A Multi-site Bridging Study of Nalfurafine Hydrochloride Orally Disintegrating Tablet
|
Phase 3 | |
Completed |
NCT02143973 -
Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus
|
Phase 2/Phase 3 | |
Terminated |
NCT01660243 -
Efficacy and Safety of MT-9938 for Treatment of Uremic Pruritus in Subjects With End-stage Renal Disease Receiving Hemodialysis
|
Phase 2 | |
Completed |
NCT06159686 -
The Efficacy of Hemp-containing Cream Versus Placebo in the Treatment of Uremic Pruritus
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05525234 -
A Study of Thalidomide in the Treatment of Refractory Uremic Pruritus
|
Phase 4 | |
Completed |
NCT03002233 -
TRK-820 Study in Subjects on Hemodialysis With or Without Uremic Pruritus
|
Phase 1 | |
Completed |
NCT03998163 -
CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
|
Phase 3 | |
Active, not recruiting |
NCT05885737 -
Phase 3 Study of Difelikefalin in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus
|
Phase 3 | |
Recruiting |
NCT04393675 -
Study to Investigate the Safety of LT5001 Drug Product for Uremic Pruritus in Hemodialysis Patients
|
Phase 1/Phase 2 | |
Completed |
NCT03576235 -
Safety and Efficacy of PG102P for Uremic Pruritus in HD Patients
|
N/A | |
Completed |
NCT05575193 -
Acupressure on Uremic Pruritus and Sleep Quality Among Patients Receiving Hemodialysis
|
N/A | |
Completed |
NCT02858726 -
Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
|
Phase 2/Phase 3 | |
Completed |
NCT02143648 -
Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus
|
Phase 2/Phase 3 | |
Completed |
NCT00494975 -
The Effect of Phototherapy on Pruritus of Patients With Chronic Kidney Disease
|
N/A | |
Completed |
NCT03758079 -
Comparison of Gabapentin With Doxepin in the Management of Uremic Pruritus
|
Phase 4 | |
Completed |
NCT02229929 -
Safety and Pharmacokinetics of IV CR845 in Hemodialysis Patients, and Its Efficacy in Patients With Uremic Pruritus
|
Phase 2 | |
Completed |
NCT04639674 -
AST-120 in Hemodialysis Patients With Uremic Pruritus
|
Phase 4 | |
Completed |
NCT03636269 -
CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
|
Phase 3 | |
Completed |
NCT04711603 -
A Phase III Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus.
|
Phase 3 | |
Completed |
NCT03422653 -
A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1)
|
Phase 3 |